PinnyPeptide

Bronchogen vs Prostamax

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

Bronchogen

Bioregulators

Khavinson short peptide bioregulator targeting bronchial epithelium and lung tissue.

Peptide B

Prostamax

Bioregulators

Khavinson short peptide bioregulator targeting prostate tissue.

Typical vial

20 mg

Typical dose

1,000-5,000 mcg

Half-life

Short (minutes); biological effect persists longer via gene-expression modulation

FDA status

Not FDA approved.

Typical vial

20 mg

Typical dose

1,000-5,000 mcg

Half-life

Short (minutes); biological effect persists via gene-expression modulation

FDA status

Not FDA approved.

Bronchogen effects

  • Reported restoration of bronchial epithelial function
  • Improvement in pulmonary function tests (Russian observational data)
  • Reduction in COPD/bronchitis exacerbation frequency
  • Improved dyspnea and exercise tolerance
  • Anti-inflammatory effects in bronchial tissue

Prostamax effects

  • Reported improvement in chronic prostatitis symptoms
  • Possible reduction in BPH-related urinary symptoms
  • Anti-inflammatory effects in prostate tissue
  • Modulation of prostate gene expression
  • Russian observational support for elderly male prostate health

Bronchogen side effects

  • Generally well-tolerated in Russian clinical use
  • Mild injection-site reactions
  • Occasional allergic reactions (rare)
  • Limited Western safety validation

Prostamax side effects

  • Generally well-tolerated in Russian clinical use
  • Mild injection-site reactions
  • Limited Western safety validation
  • Not a substitute for proper urological evaluation

Bronchogen dosing ranges

Bronchial function support

1-5 mg · Once daily (SubQ) or sublingual · 10-20 day cycles, repeated 2-3 times per year

Prostamax dosing ranges

Prostate health support

1-5 mg · Once daily (SubQ) or sublingual · 10-20 day cycles, repeated 2-3 times per year

Full Bronchogen guide → Full Prostamax guide →

Bronchogen vs Prostamax — common questions

What is the difference between Bronchogen and Prostamax?

Bronchogen: Khavinson short peptide bioregulator targeting bronchial epithelium and lung tissue. Typical dose 1,000-5,000 mcg. Prostamax: Khavinson short peptide bioregulator targeting prostate tissue. Typical dose 1,000-5,000 mcg. Both fall under the Bioregulators category.

Can you stack Bronchogen and Prostamax?

Stacking Bronchogen with Prostamax is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, Bronchogen or Prostamax?

Bronchogen is typically dosed: Once daily (SubQ) or sublingual for Bronchial function support. Prostamax is typically dosed: Once daily (SubQ) or sublingual for Prostate health support.

Are Bronchogen and Prostamax FDA approved?

Bronchogen: Not FDA approved. Prostamax: Not FDA approved.

Related peptide comparisons

bronchogen vs cardiogenbronchogen vs cartalaxbronchogen vs cortagenbronchogen vs crystagenbronchogen vs ovagenbronchogen vs pancragen

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free